IGKV1-5

Across TCGA pan-cancer cohorts, IGKV1-5 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated IGKV1-5 data layer compared with 22 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher IGKV1-5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGKV1-5 expression acts as an unfavorable survival marker.

BLCA, KIRP, and COAD are the cancer types where IGKV1-5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.141	0.710	<.001	39	view →
KIRP	OS	Median	All	0.148	0.904	<.001	30	view →
COAD	OS	Median	All	0.001	0.871	<.001	18	view →
LUSC	OS	Median	All	0.282	0.661	.017	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

IGKV1-5–BLCA (OS)

Open the BLCA breakdown →